FDA Opens Public Docket on Drug Repurposing to Close Labeling Gaps for Approved Medicines

Regulatory affairs teams with approved assets in metabolic disease, rare disease, or neurodegenerative conditions now have a formal channel to shape how the FDA structures its drug repurposing framework, following the agency's May 11 announcement of a public docket soliciting input on new indications and populations for already-approved drugs.

The initiative sits within a broader FDA effort to modernize drug labeling under existing statutory authorities, including the MODERN Labeling Act of 2020 and the Best Pharmaceuticals for Children Act. The agency's Project Renewal, which has already updated labeling for several oncology products, provides a working precedent for what evidence-supported lifecycle extension can look like in practice. Regulatory leads should read this docket as a signal that the agency is prepared to act on labeling revisions where the science exists but commercial incentives have not driven sponsors to pursue them.

The FDA is explicitly targeting three evidence tiers: candidates where sufficient data may already support a new use; candidates with promising preliminary clinical data from observational studies or case series; and candidates supported by preclinical findings, including outputs from AI and machine learning tools. That last category is notable for development teams running computational screening programs against legacy compounds.

Priority disease areas named by the agency include metabolic diseases, neurodegenerative conditions, substance use disorders, women's and men's health, and rare diseases. The docket also invites comment on structural barriers limiting repurposing development, particularly where publicly available evidence exists but no sponsor has a commercial incentive to file. For QA and regulatory leads, that framing suggests the agency may be considering mechanisms to facilitate agency-initiated labeling updates, a posture with direct implications for post-approval change management under 21 CFR Part 314.

The effort is further anchored by a September 2025 federal strategy directive instructing FDA and the National Institutes of Health to jointly investigate repurposed drug opportunities for chronic disease, with harmonized clinical trial designs aimed at achieving approval. Collaboration with the Centers for Medicare and Medicaid Services is also referenced, pointing toward potential reimbursement alignment for repurposed indications.

Electronic submissions to docket FDA-2025 can be filed via regulations.gov; written submissions go to Dockets Management Staff (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Portfolio reviews against the agency's named priority areas, with supporting evidence packages assessed for submission readiness, represent the near-term action point for regulatory affairs functions.

Source: FDA press announcement via FDA.gov What's New: Drugs RSS Feed, May 11, 2026.